EMA Assesses Eli Lilly’s COVID-19 Antibody Cocktail

The European Medicines Agency (EMA) is reviewing Eli Lilly’s antibody cocktail as a potential treatment for COVID-19 patients who don’t require supplemental oxygen and are at high risk of progressing to severe disease.

Preliminary study data on Lilly’s bamlanivimab/etesevimab cocktail showed the combination treatment reduced the risk of COVID-19 hospitalization or death by 70 percent.

The EMA’s human medicines committee is considering a recommendation for conditional marketing authorization and the FDA is reviewing an Emergency Use Authorization (EUA) for the combination treatment.